Comprehensive genomic profiling (CGP) of tumors is an important aspect of determining therapy for individuals with advanced cancer. It is covered by Medicare for patients with advanced cancers seeking further cancer treatment, yet many commercial health insurance providers have limited coverage to small, targeted genetic panels.

This webinar will describe the difference between CGP and other types of genetic tests for cancer, identify how it helps patients and clinicians, and discuss therapies that rely on CGP as a diagnostic. Health insurance providers are often challenged with how to evaluate the clinical utility and clinical value of tests that include many genes, and this presentation will review Medicare and global models that can be utilized to evaluate CGP for advanced cancer.

Attendees will be able to:

  • Describe comprehensive genomic profiling for advanced cancer
  • Understand how treatment and outcomes can improve using CGP
  • Identify new models to analyze clinical value from the insurance provider perspective


  • Susan Hsiao, MD, PhD
    Assistant Professor, Department of Pathology and Cell Biology
    Columbia University Medical Center
  • Kristine Bordenave, MD, FACP
    Strategic Consultant
    KKBordenave Consulting Group, LLC‌

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.